SI1696909T1 - Derivati benzotiazola za zdravljenje diabetesa - Google Patents

Derivati benzotiazola za zdravljenje diabetesa

Info

Publication number
SI1696909T1
SI1696909T1 SI200430550T SI200430550T SI1696909T1 SI 1696909 T1 SI1696909 T1 SI 1696909T1 SI 200430550 T SI200430550 T SI 200430550T SI 200430550 T SI200430550 T SI 200430550T SI 1696909 T1 SI1696909 T1 SI 1696909T1
Authority
SI
Slovenia
Prior art keywords
unsubstituted
substituted
treatment
benzothiazole derivatives
group
Prior art date
Application number
SI200430550T
Other languages
English (en)
Inventor
Pascale Domaine De La Gaillard
Jean-Pierre Gotteland
Pierre-Alain Vitte
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of SI1696909T1 publication Critical patent/SI1696909T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SI200430550T 2003-09-12 2004-09-08 Derivati benzotiazola za zdravljenje diabetesa SI1696909T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03102740 2003-09-12
PCT/EP2004/052090 WO2005025567A1 (en) 2003-09-12 2004-09-08 Benzothiazole derivatives for the treatment of diabetes
EP04787110A EP1696909B1 (en) 2003-09-12 2004-09-08 Benzothiazole derivatives for the treatment of diabetes

Publications (1)

Publication Number Publication Date
SI1696909T1 true SI1696909T1 (sl) 2008-02-29

Family

ID=34306921

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200430550T SI1696909T1 (sl) 2003-09-12 2004-09-08 Derivati benzotiazola za zdravljenje diabetesa

Country Status (18)

Country Link
US (2) US20070088017A1 (sl)
EP (1) EP1696909B1 (sl)
JP (1) JP5021307B2 (sl)
AT (1) ATE378047T1 (sl)
AU (1) AU2004271740B2 (sl)
CA (1) CA2534314C (sl)
CY (1) CY1107820T1 (sl)
DE (1) DE602004010178T2 (sl)
DK (1) DK1696909T3 (sl)
ES (1) ES2297494T3 (sl)
HK (1) HK1096594A1 (sl)
HR (1) HRP20070527T3 (sl)
IL (1) IL174250A (sl)
NO (1) NO20061600L (sl)
PL (1) PL1696909T3 (sl)
PT (1) PT1696909E (sl)
SI (1) SI1696909T1 (sl)
WO (1) WO2005025567A1 (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838522B2 (en) * 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
JP5345534B2 (ja) 2006-08-24 2013-11-20 ユニバーシティ オブ テネシー リサーチ ファウンデーション 置換アシルアニリドおよびそれらの使用方法
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2137173A2 (en) * 2007-04-17 2009-12-30 Laboratoires Serono SA Process for the preparation of piperazine benzothiazoles
UA100527C2 (en) * 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9604916B2 (en) 2012-07-13 2017-03-28 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂
WO2017025980A2 (en) * 2015-08-12 2017-02-16 Shoolineuniversity Of Biotechnology And Management Sciences Novel benzothiazole derivatives with enhanced biological activity
US11970467B1 (en) 2023-10-13 2024-04-30 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound
US11905260B1 (en) 2023-10-13 2024-02-20 King Faisal University N′-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1176269A (en) * 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
JP4589002B2 (ja) * 2001-12-07 2010-12-01 メルク セローノ ソシエテ アノニム 強皮症の治療のためのベンザゾール誘導体
JP4523289B2 (ja) * 2002-04-25 2010-08-11 メルク セローノ ソシエテ アノニム 脳虚血障害又はｃｎｓ障害の処置のための薬剤としてのピペラジンベンゾチアゾール

Also Published As

Publication number Publication date
ATE378047T1 (de) 2007-11-15
AU2004271740A1 (en) 2005-03-24
DE602004010178T2 (de) 2008-09-11
US20140107116A1 (en) 2014-04-17
DE602004010178D1 (de) 2007-12-27
US20070088017A1 (en) 2007-04-19
NO20061600L (no) 2006-04-07
EP1696909B1 (en) 2007-11-14
IL174250A (en) 2011-01-31
IL174250A0 (en) 2006-08-01
HRP20070527T3 (en) 2007-12-31
DK1696909T3 (da) 2008-01-02
CA2534314C (en) 2012-11-13
AU2004271740B2 (en) 2010-10-28
PL1696909T3 (pl) 2008-04-30
CA2534314A1 (en) 2005-03-24
EP1696909A1 (en) 2006-09-06
PT1696909E (pt) 2007-12-21
JP2007505083A (ja) 2007-03-08
HK1096594A1 (en) 2007-06-08
CY1107820T1 (el) 2013-06-19
JP5021307B2 (ja) 2012-09-05
ES2297494T3 (es) 2008-05-01
WO2005025567A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
HK1096594A1 (en) Benzothiazole derivatives for the treatment of diabetes
NO20061614L (no) Benzimidazolacetonitriler
ATE557030T1 (de) Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
BRPI0406761A (pt) Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
EA200601869A1 (ru) Карбоновые кислоты
NO20083026L (no) Terapeutisk middel for diabetes
BRPI0412997A (pt) derivados de dióxido de tiazol-benzoisotiazol substituìdos, método para produzir os mesmos e seu uso
MXPA05009356A (es) Derivados de c-glicosido y sales de los mismos.
NO20080728L (no) Nye 1,4-benzotiazepin-1,1-dioksidderivater som har forbedrede egenskaper, fremgangsmate for fremstilling derav, medikamenter inneholdende nevnte forbindelsene og anvendelse derav
NO20065926L (no) Substituerte oksazolbenzoisotiazoldioksidderivater samt fremgangsmate for fremstilling og anvendelse derav
WO2010045303A3 (en) Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
PA8566201A1 (es) Nuevos derivados de piridina y quinolina
NO20085067L (no) 4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20061599L (no) Benzoksazol acetonitriler
MA28339A1 (fr) Derives de l'acide 7- amino-4-quinolone-3-carboxylique substitues de maniere heterocyclique, methode pour leur production et leur utilisation en tant que medicaments
EA200400882A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ МЕТИЛЕНАМИДА В КАЧЕСТВЕ МОДУЛЯТОРОВ ПРОТЕИНТИРОЗИНФОСФАТАЗ ( PTPs )
ATE455772T1 (de) Alkinylarylcarbonsäureamide
NO20074639L (no) Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
TW200609228A (en) Substituted n-acyl-2-aminothiazoles
TW200740786A (en) Novel cercosporamide derivatives
BRPI0607558A2 (pt) derivados do ácido aminobutanóico, inibidor da carnitina palmitoil transferase(cpt)
TWI256952B (en) Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders
NO20054148L (no) Nytt medikament